Prevalence of molecular subtypes of invasive breast cancer: A retrospective study

Abstract

a b s t r a c tBackground: Classification of breast cancers into different molecular subtypes using immunohistochemistry as a surrogate tool to DNA microarray technology has been identified. Aim of this study was to find the precise prevalence of molecular subtypes of invasive breast carcinoma using immunohistochemistry and to correlate it with histological and clinical prognostic factors.Methods: A descriptive study design wherein 56 breast carcinoma cases diagnosed between May 2012 and Apr 2014 were reviewed and molecular subtyped using relevant immunohistochemical markers. Age, histological type, tumor size, tumor grade, lymphovascular emboli (LVE), nodal status and basal marker expressions were analyzed for all cases.Correlations between molecular subtypes and clinico-pathological characteristics were evaluated statistically.Results: In our study group, average age of patients was 50.5 years and most of patients were diagnosed in stage II (54%). Luminal A subtype was most prevalent 34%, followed by m e d i c a l j o u r n a l a r m e d f o r c e s i n d i a 7 1 ( 2 0 1 5 ) 2 5 4 e2 5 8http://dx

Biological and Clinicopathological Characteristics of Breast Cancer at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia

“…This disagrees with other studies from India where 34% of the cases were luminal A, followed by TNBC (25%); whereas luminal B and Her2/neu subtypes had same prevalence (18% of each) [41]. Studies in Ghana indicated 25.6% of luminal A, 12.2% of luminal B and 49.9% of TNBC (27).…”

Clinicopathological features and survival of early stage breast cancer in northwest China: A population‐based retrospective study of 1287 patients

“…9.0%, and TN 17.7% versus 16.5%, respectively. Two studies from India demonstrated fewer luminal types: luminal A 43.8% and 34%, luminal B 14.8% and 18%, Her2 overexpression 16.1% and 18%, TN 25.3% and 25% . Data from Switzerland and Germany included more patients with luminal types, especially luminal A, which seemed to offer a better prognosis.…”

Immunohistochemical Differentiation of Triple Negative Breast Cancer

“…The basal-like tumors make up the biggest part of the group of TNT (70%-90%), while the rest are non basal-like. The basal-like subtype represents a homogeneous group of tumors sharing a common genetic profile, treatment response and prediction of the course of illness 5,11,13,14 . So far, there has not been enough information about difference in the malignant potential of TNT considering the origin of cancer cells, and the question being posed is whether differences in the prognosis and treatment among a small share of patients with triple negative cancer are a result of the malignant potential within the TNT considering their basal-like and non basal-like origin.…”

“…Generally speaking, increasing the number of markers increases the test specificity and sensitivity 10 . However, as there is no general consensus on the criteria for identifying basal-like tumors through immunohistochemical analysis, it is recommendable to use a limited number of markers, such as CK 5/6, CK 14, CK 17, P-cadherin and EGFR 5,11 . The immunohistochemical reaction was positive for CK 5/6 in 37%, for CK14 in 50.86% and for P-cadherin in 68.34% of cases.…”

“…However, as there is no such consensus on the criterion for identifying basal like tumors through immunohistochemical analysis, it is recommendable to use a limited number of markers, such as: CK 5/6, CK 14, CK 17, P-cadherin and EGFR 5,11 . In order to determine the best combination, the one that would be closest to the results of the gene expression analysis, in this study CK 5/6, CK 14 and P-cadherin were used as markers for identifying basal-like tumors.…”